Geode Capital Management’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.57M Buy
3,107,096
+814,686
+36% +$3.46M ﹤0.01% 2402
2025
Q4
$8.28M Buy
2,292,410
+275,025
+14% +$1.2M ﹤0.01% 2500
2025
Q3
$7.61M Buy
2,017,385
+82,505
+4% +$319K ﹤0.01% 2572
2025
Q2
$7.49M Buy
1,934,880
+228,995
+13% +$1.24M ﹤0.01% 2527
2025
Q1
$8.53M Buy
1,705,885
+47,379
+3% +$300K ﹤0.01% 2390
2024
Q4
$12M Sell
1,658,506
-9,498
-0.6% -$72.6K ﹤0.01% 2256
2024
Q3
$10.2M Buy
1,668,004
+74,194
+5% +$503K ﹤0.01% 2363
2024
Q2
$10.6M Buy
1,593,810
+357,012
+29% +$2.63M ﹤0.01% 2291
2024
Q1
$12.6M Buy
1,236,798
+43,270
+4% +$440K ﹤0.01% 2188
2023
Q4
$13.4M Buy
1,193,528
+140,192
+13% +$585K ﹤0.01% 2157
2023
Q3
$2.74M Buy
1,053,336
+83,475
+9% +$239K ﹤0.01% 2954
2023
Q2
$3.42M Buy
969,861
+487,500
+101% +$2.19M ﹤0.01% 2898
2023
Q1
$2.04M Buy
482,361
+43,479
+10% +$517K ﹤0.01% 3023
2022
Q4
$7.22M Sell
438,882
-37,185
-8% -$418K ﹤0.01% 2459
2022
Q3
$6.08M Buy
476,067
+96,236
+25% +$1.42M ﹤0.01% 2563
2022
Q2
$4.44M Sell
379,831
-261,990
-41% -$1.62M ﹤0.01% 2765
2022
Q1
$3.91M Buy
641,821
+8,777
+1% +$64.6K ﹤0.01% 2935
2021
Q4
$5.8M Sell
633,044
-25,808
-4% -$274K ﹤0.01% 2815
2021
Q3
$7.45M Buy
658,852
+123,336
+23% +$1.5M ﹤0.01% 2676
2021
Q2
$5.27M Buy
535,516
+286,386
+115% +$3.92M ﹤0.01% 2863
2021
Q1
$3.52M Buy
249,130
+50,872
+26% +$822K ﹤0.01% 2953
2020
Q4
$2.24M Buy
198,258
+18,687
+10% +$220K ﹤0.01% 3023
2020
Q3
$2.37M Buy
179,571
+90,537
+102% +$1.81M ﹤0.01% 2786
2020
Q2
$953K Buy
89,034
+2,859
+3% +$15.7K ﹤0.01% 3153
2020
Q1
$276K Hold
86,175
﹤0.01% 3452
2019
Q4
$162K Hold
86,175
﹤0.01% 3869
2019
Q3
$168K Buy
86,175
+1,357
+2% +$3.01K ﹤0.01% 3835
2019
Q2
$201K Buy
84,818
+35,644
+72% +$95.4K ﹤0.01% 3791
2019
Q1
$142K Buy
49,174
+33,062
+205% +$98.5K ﹤0.01% 3822
2018
Q4
$33K Buy
+16,112
New +$57K ﹤0.01% 4048
2018
Q3
Sell
-1,022
Closed -$13K 4123
2018
Q2
$13K Sell
1,022
-1,276
-56% -$25.1K ﹤0.01% 4050
2018
Q1
$79K Sell
2,298
-1,020
-31% -$51.1K ﹤0.01% 3885
2017
Q4
$198K Sell
3,318
-335
-9% -$21.4K ﹤0.01% 3680
2017
Q3
$254K Sell
3,653
-61
-2% -$4.54K ﹤0.01% 3591
2017
Q2
$356K Sell
3,714
-768
-17% -$128K ﹤0.01% 3488
2017
Q1
$1.09M Buy
4,482
+2,842
+173% +$1.52M ﹤0.01% 2980
2016
Q4
$1.6M Buy
1,640
+376
+30% +$337K ﹤0.01% 2756
2016
Q3
$1.1M Buy
1,264
+13
+1% +$10.2K ﹤0.01% 2894
2016
Q2
$915K Buy
1,251
+253
+25% +$173K ﹤0.01% 2942
2016
Q1
$566 Hold
998
﹤0.01% 3157
2015
Q4
$569K Hold
998
﹤0.01% 3211
2015
Q3
$398K Buy
998
+270
+37% +$128K ﹤0.01% 3335
2015
Q2
$392K Hold
728
﹤0.01% 3309
2015
Q1
$355K Hold
728
﹤0.01% 3338
2014
Q4
$395K Hold
728
﹤0.01% 3288
2014
Q3
$388K Buy
728
+147
+25% +$76.9K ﹤0.01% 3275
2014
Q2
$245K Hold
581
﹤0.01% 3446
2014
Q1
$319K Hold
581
﹤0.01% 3334
2013
Q4
$324K Hold
581
﹤0.01% 3253
2013
Q3
$366K Buy
581
+108
+23% +$61.9K ﹤0.01% 3085
2013
Q2
$225K Buy
+473
New +$235K ﹤0.01% 3190

Other funds holding ALT

Geode Capital Management's ALT Position: Q1 2026 in Review

Geode Capital Management increased its Altimmune (ALT) stake by 36% in Q1 2026, buying an estimated $3.46M and bringing the position to 3,107,096 shares worth $9.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2402.

Geode Capital Management first reported a position in ALT in Q2 2013 and has held it in 51 quarters since. The position peaked at $13.4M in Q4 2023. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Geode Capital Management held 3,107,096 shares of Altimmune worth $9.57M as of Q1 2026.
  • Geode Capital Management bought 814,686 Altimmune shares in Q1 2026, an estimated $3.46M.
  • Altimmune made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2402 holding.
  • Geode Capital Management first reported a position in Altimmune in Q2 2013 and has held it in 51 quarters since.
  • Geode Capital Management's Altimmune position peaked at $13.4M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.